(Avelumab)Biosimilar Reference Antibody-GS40049主打 新品

货号：GS40049

Avelumab is a fully human IgG1 lambda monoclonal antibody that functions as an immune checkpoint inhibitor. It specifically targets Programmed Death-Ligand 1 (PD-L1). By binding to PD-L1, it blocks its interaction with the PD-1 and B7.1 (CD80) receptors, thereby releasing the “brakes” on T cells and restoring anti-tumor immune responses. Avelumab is unique among early PD-1/PD-L1 inhibitors as it retains a functional Fc region capable of inducing Antibody-Dependent Cellular Cytotoxicity (ADCC), which may contribute to its mechanism by depleting PD-L1-positive tumor cells or immune cells. It is approved by regulatory agencies (including FDA and EMA) for the treatment of metastatic Merkel cell carcinoma (MCC), advanced urothelial carcinoma (UC), and advanced renal cell carcinoma (RCC) (in combination with axitinib). It was the first FDA-approved therapy for metastatic MCC.